Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. - Wikidata - wikimedia - TriplyDB

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

http://www.wikidata.org/entity/Q38166125

about

Persistence and compliance with medication management in the treatment of overactive bladder The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder Symptomatic management in multiple sclerosis Clinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome Mirabegron in overactive bladder patients: efficacy review and update on drug safety CUA guideline on adult overactive bladder Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.Lower urinary tract dysfunction in pelvic gynecologic cancer: the role of urodynamics.Acupuncture for adults with overactive bladder: a systematic review protocol.Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom Highlights of the university of toronto urology update 2014.Postmenopausal overactive bladder Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.Comparison of solifenacin and fesoterodine in treatment of overactive bladder.Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art.Cholinergic Targets in Lung Cancer High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.Profile of mirabegron in the treatment of overactive bladder: place in therapy.Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence.Cost-effectiveness of novel therapies for overactive bladder.An update on the pharmacotherapy for lower urinary tract dysfunction.Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.Guideline of guidelines: urinary incontinence.Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.The impact of persistence with mirabegron usage versus switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.Delivery methods for drugs used in the treatment of overactive bladder.The role of acupuncture in managing overactive bladder; a review of the literature.Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).Current and future pharmacotherapy for treating overactive bladder.

P2860

Q26765014-BACD45DE-103D-48DD-8215-2E722175A94B Q26770419-7775297D-3656-4F52-AF53-481D950E53A8 Q26779897-D1D5DC54-2EA6-4030-8945-9BC8AF689347 Q26783536-0F5D105D-588F-40D2-A4A8-B3DB6AA74FB3 Q28072230-411FB5DA-1E77-43FC-9F3F-A1C0F832C858 Q33665026-2CC5C958-EBEE-4409-961F-FC20C2A7C6E7 Q33835874-F1C55BD9-F53E-4FDA-B3DF-E5E013349176 Q33863110-9AB80468-F95C-4E57-BF86-3091C1BBB468 Q34652222-29DE8BBB-5870-47CD-9EC6-79CB8BD68B7B Q34903525-6E2949CE-F9F5-48BF-B746-FA7B87E649F7 Q34990256-FA1A1EC8-0145-492E-B8A1-64753BC7D0AF Q35100023-6F1D832C-C2F1-4D4D-A0BF-E3CAD76D0CD6 Q35157329-ECCC00E5-B91E-4F57-8730-5E5CF799AE6E Q35657577-45114192-EB3B-4AAE-80AE-10DD94D5324C Q36086072-5E5DA5B5-DB12-4D5A-B8AC-23969560DA41 Q36210264-C880C4E8-D479-465E-86EE-C66278BBB569 Q36326096-B173F2D4-FFD0-47E1-B37C-8A6158834B4D Q36338313-A557046F-1B97-4B8E-8C2B-44EA369FA720 Q36625281-478ACA7E-4D11-4BE0-BD42-6DCA708C78E8 Q36689405-D3469DEF-D4C4-4965-B4A7-2B166E42F24D Q36872911-7ADFAA2C-088D-49AC-8C14-1D01B2CE7AAF Q37127226-7C2D0BBC-CCB2-4D80-B53A-1E232CFDF57A Q37409521-82651A4B-B25E-4665-9CED-A9E806AED5A5 Q37570247-29902073-19FE-46DF-996D-54C256A1DE50 Q37664787-D4DD9DC8-60E4-45C0-8E59-A13A450EF1AA Q37699850-DA577D4B-8E83-4BF7-ABC0-EA0CDA90F28E Q38210254-A9C25BC2-A8D9-4029-A82D-FB5C976C1AA3 Q38263375-61EF3FE4-8CBC-4FD4-8BD3-B5F671637697 Q38306806-CF635DAF-72A1-4D71-B919-79711AB46DCC Q38511811-876B2820-13F5-4A20-B133-B97D627FBD19 Q38570412-57A0F1B1-AE47-4C1E-9897-6417F467B230 Q38577301-D2E096E6-FE09-46EA-8054-A0CAF09A6DEC Q38626236-0355B6CC-D2B5-4BA4-BDF3-C717B431EAEA Q38665319-AFEA6EFA-CA12-43A8-87AB-93EFE4E05015 Q38689041-BBE8CEC6-6429-440F-8B1D-E13C27F2B920 Q38705836-920A1227-E10E-4762-8A23-EA1AE2DE2059 Q38711099-ABE84FF7-668D-448B-B6D0-02B89F179DEA Q38765381-65A9FCFD-1961-44DD-8463-7A8C5576A1EA Q38832902-BDDD726E-C7E8-4CF7-8657-C380EE2E61F3 Q38851523-FFB368BC-6C6A-4E02-84EB-065882B8729C

P2860

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

http://www.wikidata.org/entity/Q38166125

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Comparative efficacy and safet ...... nd mixed treatment comparison.

@en

type

label

Comparative efficacy and safet ...... nd mixed treatment comparison.

@en

prefLabel

Comparative efficacy and safet ...... nd mixed treatment comparison.

@en

P1433

Q38166125-8CD65B4C-18D7-440C-BA62-049491A733B3

P1476

Q38166125-C568BC03-B61F-4163-AABA-B486B84D89AA

P2093

Q38166125-4E9D1838-7AF4-44D9-AFBC-20C2B6AAF6B3

Q38166125-5D7C2D87-0802-497D-80E1-9A85D4E10365

Q38166125-7920739C-7F10-40C7-966D-B515C5197947

Q38166125-7B98C9EA-3AD8-4AF2-B98E-E42F02899C12

Q38166125-9046FBF5-B8B0-44A3-92E4-A9260514A741

Q38166125-993B24AD-0CBA-4CBB-8187-54F9780D6E19

Q38166125-B3F897CB-1521-4090-87E1-5F231FB4CB82

Q38166125-DAFB1C0E-4488-4CAF-930B-67090C470BB9

P304

Q38166125-950B0604-9A45-44BC-98F2-B6CDB51F4C15

P31

Q38166125-544D73FC-BDA9-4652-B3D0-859FA10C944A

P356

Q38166125-2C30BF43-B03D-46A1-8CBF-CCF9505B6C43

P407

Q38166125-14A0EA34-9431-48F3-8320-26446BDB99CD

P433

Q38166125-0FE6545A-7D53-4258-B0BC-0A19E13E04E6

P478

Q38166125-172236FA-DD6F-4ADA-A6C1-8CB6E3740E05

P577

Q38166125-E758E78D-5C40-4876-9A7F-FEDC097ACEA8

P698

Q38166125-4EB84C7D-2414-4209-ADA6-A85825802794

P356

J.EURURO.2013.11.010

P1433

European Urology

P1476

Comparative efficacy and safet ...... nd mixed treatment comparison.

@en

P2093

Emad Siddiqui

http://www.w3.org/2001/XMLSchema#string

Isaac Odeyemi

http://www.w3.org/2001/XMLSchema#string

Jameel Nazir

http://www.w3.org/2001/XMLSchema#string

Katia Desroziers

http://www.w3.org/2001/XMLSchema#string

Khaled Maman

http://www.w3.org/2001/XMLSchema#string

Mohamed-Elmoctar Neine

http://www.w3.org/2001/XMLSchema#string

Samuel Aballea

http://www.w3.org/2001/XMLSchema#string

Zalmai Hakimi

http://www.w3.org/2001/XMLSchema#string

P304

755-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.11.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24275310

http://www.w3.org/2001/XMLSchema#string